Compare PK & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PK | ANIP |
|---|---|---|
| Founded | 1946 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | PK | ANIP |
|---|---|---|
| Price | $10.59 | $81.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $11.45 | ★ $99.29 |
| AVG Volume (30 Days) | ★ 3.1M | 468.6K |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | ★ 9.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $2,541,000,000.00 | $826,880,000.00 |
| Revenue This Year | $0.11 | $43.41 |
| Revenue Next Year | $2.07 | $9.66 |
| P/E Ratio | ★ N/A | $48.82 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $8.27 | $52.50 |
| 52 Week High | $16.23 | $99.50 |
| Indicator | PK | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 36.38 |
| Support Level | $10.44 | $77.99 |
| Resistance Level | $10.78 | $85.09 |
| Average True Range (ATR) | 0.30 | 2.61 |
| MACD | 0.04 | 0.19 |
| Stochastic Oscillator | 64.35 | 41.60 |
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.